SpreadLove In Organizations - Healthcare Leadership

In this episode of Spread Love in Organizations, host Naji Gehchan welcomes Nelson Repenning, Faculty Director of the MIT Leadership Center and Distinguished Professor at MIT Sloan, to explore why so many organizations struggle to turn proven management ideas into real, sustained impact. Drawing on decades of research in system dynamics and organizational design, Nelson unpacks the hidden forces that keep teams trapped in constant firefighting despite the best intentions, smart people, and well-documented best practices. At the heart of the conversation is Nelson’s work on dynamic work design, the foundation of his new book There’s Got to Be a Better Way. He explains the “capability trap” that pulls leaders toward short-term fixes and away from long-term learning, and introduces five practical principles that help organizations escape this cycle: solving the right problem, structuring work for discovery, connecting the human chain, regulating flow, and using visual management. Through real-world examples, from manufacturing to healthcare and drug development, Nelson shows how small, well-designed changes can unlock surprisingly large gains in performance, engagement, and impact. The discussion also dives into leadership, healthcare complexity, and the thoughtful use of AI, emphasizing that effective change doesn’t come from top-down initiatives or copying “best practices,” but from leaders who are willing to go see the work, listen deeply, and develop people. Nelson closes with a powerful reminder: great leadership is not about issuing targets or demanding solutions, but about creating the conditions where people can surface problems, learn together, and do meaningful work. A compelling episode for anyone seeking to build more humane, resilient, and effective organizations. "Most organizations don’t have a strategy problem, they have a flow problem. We take on far too much work, and everything grinds to a halt." MEET OUR GUEST Nelson Repenning, Faculty Director of the MIT Leadership Center, and the School of Management Distinguished Professor of System Dynamics and Organization Studies at the MIT Sloan School of Management. Nelson P. Repenning is the Faculty Director of the MIT Leadership Center, and the School of Management Distinguished Professor of System Dynamics and Organization Studies at the MIT Sloan School of Management. His early work focused on understanding the inability of organizations to leverage well-established tools and practices. He has worked extensively with organizations trying to develop new capabilities in both manufacturing and new product development. Nelson has also studied the failure to use the safety practices that often lead to industrial accidents and has helped investigate several major incidents. This line of research has been recognized with several awards, including best paper recognition from both the California Management Review and the Journal of Product Innovation Management. Building on his earlier work, Nelson now focuses on developing the theory and practice of Dynamic Work Design—a new approach to designing work that is both effective and engaging— and Dynamic Management Systems, a method for ensuring that day-to-day work is tightly linked to the strategic objectives of the firm. His book (co-authored with Don Kieffer) There Has Got to Be a Better Way describing Dynamic Work Design will be published by Public Affairs in 2025. He is also a partner at ShiftGear Work Design and serves as its chief social scientist. In 2003, Nelson received the International System Dynamics Society’s Jay Wright Forrester Award, which recognizes the best work in the field in the previous five years. In 2011 he received the Jamieson Prize for Excellence in Teaching. He was recently recognized by Poets and Quants as one of the country's top instructors in executive education. Nelson is also an avid bike racer and regularly competes in Masters cycling events. He holds a BA in economics from Colorado College and a PhD in operations management and system dynamics from MIT.

In this deeply human and wide-ranging conversation, Giovanni Abbadessa shares the personal journey that shaped his vocation as a physician, scientist, and leader. Growing up in Naples as the son of a prominent hematologist, Giovanni initially resisted medicine, only to discover his calling through lived experiences that blended science with humanity. A transformative humanitarian trip to India, working alongside communities affected by leprosy, profoundly reshaped his understanding of dignity, service, and impact. This experience, combined with early clinical exposure, led him to choose oncology, not just for the science, but for the deep, often spiritual connection with patients and families at life’s most vulnerable moments. Giovanni traces his evolution from clinician to translational scientist and biotech leader, moving across Italy and the United States, from hospitals to research labs, and ultimately into biotech and pharma. He reflects on pivotal moments, from enrolling patients in landmark oncology trials, to building basic science programs from scratch during his PhD in Philadelphia, to navigating the realities of startup biotech during financial crises. Across academia, small biotech, and large pharma, Giovanni highlights how resilience, curiosity, and an unwavering focus on patients guided his decisions, including when to leave organizations due to poor leadership and when to stay and rebuild through trust, compassion, and shared purpose. At the heart of the episode is Giovanni’s philosophy of leadership and collaboration. Drawing from decades of nonprofit volunteering, community building, and formal leadership training at Harvard Business School, he emphasizes that “drugs don’t develop drugs. People develop drugs.” He argues that effective collaboration starts with honesty about needs, mutual respect, and trust, and that innovation requires humility, failure, and resilience. With memorable metaphors, from pizza as a catalyst for breaking silos, to leadership as a team sport rather than a solo game, Giovanni offers powerful insights for healthcare leaders on how to spread love in organizations by putting people, connection, and purpose first. "Drugs do not develop drugs. People develop drugs." MEET OUR GUEST Dr. Giovanni Abadessa, Chief Medical Officer at ModeX Therapeutics. Giovanni Abbadessa is a Medical Oncologist and PhD with 23 years drug development experience across academia, small biotech, and pharma. He is a passionate, hands-on, and entrepreneurial leader specializing in oncology, hematology, and rare disease pre-clinical and clinical (Phase 1-3) development. Giovanni has worked on the development of nearly 30 clinical and as many preclinical experimental drugs across eight classes of agents. He is known for a collaborative leadership style, growing and uniting people and science through transparent, results-driven teams. Giovanni has strong strategic, operations, business development and board management experience in both corporate and nonprofit sectors, and has led investor relations, medical affairs, and commercial assessments, enjoying a vast network of academic and industry collaborators. Presently, as Chief Medical Officer at ModeX Therapeutics, a small biotechnology firm in Weston, MA, Giovanni guides strategy and execution of a variety of clinical programs in oncology and infectious diseases. Additionally, he shapes preclinical oncology research, is responsible for business development and defines corporate strategy with the rest of the company C-Suite, aligning scientific innovation with business objectives while inspiring cross-functional teams. From 2017 to 2024, Giovanni held a series of senior leadership roles at Sanofi. As Vice President of Oncology Early Development, he was a member of the company’s executive leadership team, oversaw Phase 3 and commercial strategy, built and led an oncology team of 25 who led cross-functional work performed by ~300 people on ~20 early clinical and as many preclinical assets for solid and hematological malignancies and kidney transplant. His portfolio included small molecules, checkpoint inhibitors, ADCs, cytokines, T and NK cell engagers, intratumoral RNA, and cell therapy. He spearheaded strategy and execution for interactions with global Health Authorities, and represented Sanofi with investors, governments, and academic institutions. Prior to joining Sanofi, Giovanni spent nearly a decade at ArQule, a small biotech company where he advanced to Vice President of Clinical Development, Preclinical Research and Medical Affairs, responsible for development from basic lab research to Phase 3. He worked on MET, AKT, FGFR, Eg5, BRAF, and BTK small molecule inhibitors for cancer and rare pediatric diseases and supported business development, investor relations, people and company strategy alongside the C-Suite and the Board. Earlier, as Senior Medical Director, Clinical Development at Ziopharm Oncology, a small biotechnology company engaged in research and clinical development of novel chemo-derivatives, Giovanni spearheaded global Phase 1 and 2 clinical trials in solid and hematologic malignancies of three molecules. Giovanni spent his post-doctoral fellowship at Temple Fox Chase Cancer Center in Philadelphia, PA, leading and mentoring a small team of scientists on in vitro/in vivo gene therapy projects in cancer models and contributing to patient treatment strategy as a Visiting Oncologist. Giovanni began his Oncology career in 2001 in Milan, Italy, at the Istituto Clinico Humanitas as an Oncology Fellow and Sub-Investigator, where he led four Phase 1-3 clinical trials with small molecules and biologics. Giovanni serves as a Scientific Board member at Biond Biologics, HiFiBiO, as Scientific Committee member at the ESMO-TAT oncology conference, and as nonprofit Board Member at the Comitato Italiani all’Estero, the Scuola Piccoli Italiani di Boston, and the Professionisti Italiani a Boston. Govanni earned a PhD in Genetic Oncology from Temple University and the University of Siena, Italy, a Clinical Oncology Fellowship from the Istituto Clinico Humanitas in Milan and the University of Genoa, Italy, and an MD summa cum laude et plausum from Federico II Medical School in Naples, Italy. He speaks native Italian, fluent English and Spanish, proficient French. He published over 60 peer-reviewed articles, 120 conference abstracts (20+ presented orally), and gave ~40 conference talks.

In this episode of Spread Love in Organizations, Naji Gehchan welcomes Dr. Basil Upton, executive business director at Eli Lilly, servant leader, and catalyst behind the podcast itself. Basil shares his deeply personal journey from growing up in Maine under the guidance of his grandparents to building a 24-year career in healthcare. With a background in psychology and counseling, Basil reflects on how his desire to help others ultimately led him to pharmaceutical leadership, where purpose, performance, and people intersect. The conversation dives into Basil’s doctoral research in Educational Leadership and Organizational Innovation, which examined how leadership styles influence employee engagement during periods of both strong and weak performance. His findings challenge conventional thinking: engagement is driven not by shifting leadership styles, but by consistent servant leadership behaviors — active listening, empathy, recognition, and collaboration — especially during challenging times. Unexpectedly, Basil also highlights the powerful role of peer relationships and teamwork, sometimes outweighing even a supervisor’s influence on engagement. Together, Naji and Basil explore what it truly means to “spread love in organizations.” They challenge leaders to rethink engagement as a core performance metric, not a soft concept, and to recognize the profound impact leadership has on people’s lives beyond work. Basil leaves listeners with a call to action for healthcare leaders everywhere: seek feedback, lead with humility and accountability, embed servant leadership into the DNA of organizations, and intentionally create environments where people — and patients — can truly thrive. "The impact a leader has on someone’s life beyond work is tremendous." MEET OUR GUEST Dr. Basil Upton, Executive Business Director at Eli Lilly. Basil is a purpose driven transformational and servant leader dedicated to helping others reach their potential. He is entering his 24th year with Eli Lilly and Company where he is an executive business director. His teams have consistently exceeded performance expectations for numerous years. Basil’s work accomplishments include business director of the year, Elite coach, Platinum Performer, and recipient of several Coaching Awards. In the summer of 2024, Basil graduated from Marymount University in Arlington, VA with a doctoral degree in Educational Leadership and Organizational Innovation. He studied how a supervisor’s leadership style affects the engagement of pharmaceutical sales professionals during periods of varied sales performance for his dissertation.

In this special episode, part of our collaboration with the Biosciences Lebanese International Network (BIOLINK), I had the joy of welcoming an extraordinary leader whose career sits at the intersection of science, innovation, and purpose: Rania Abou Samra, Vice President and Head of Innovation & R&D for Nestlé Middle East and North Africa. With more than two decades of experience across global roles in nutrition, health science, and product development, Rania brings a rare blend of deep scientific expertise, entrepreneurial spirit, and human-centered leadership. Her mission has remained unwavering since her days studying Nutrition and Dietetics at AUB and later completing a PhD in Obesity and Nutrition at the University of Toronto: advancing nutrition to positively impact lives. Rania takes us on a moving journey from her childhood in northern Lebanon — where an early fascination with biology sparked her dream of fighting malnutrition — to her unexpected leap from academia into the global food industry. She shares how Nestlé’s scale allows her teams to deliver meaningful change, from fortifying foods in underserved regions to designing science-based innovations rooted in prevention rather than treatment. We dive into the evolving landscape of nutrition, from the rise of GLP-1 therapies to the growing attention on ultra-processed foods, and Rania illuminates how food companies can play a critical role in helping people lose weight safely, protect muscle mass, and maintain overall health in a world where these medications are becoming mainstream. We also explore Rania’s leadership journey across cultures — from Lebanon to Switzerland, the U.S., and now Dubai. She speaks candidly about navigating emotional expression, resilience shaped by her upbringing, and the balancing act of staying true to her identity while adapting to global environments. Her reflections on cultural agility, authenticity, and the lessons she’s carried with her across continents offer a powerful reminder of what it means to lead with purpose. Rania’s story is one of passion, courage, and an unshakeable belief in the power of science to improve lives — and it’s truly inspiring to hear how she continues to spread impact through innovation in nutrition. "Innovation without impact is meaningless; the goal is to create solutions that truly improve lives." MEET OUR GUEST Rania Abou Samra, Vice President and Head of Innovation & R&D for Nestlé Middle East and North Africa. Rania Abou Samra has served as the Vice President and Head of Innovation and Research & Development at Nestlé Middle East and North Africa since April 2025. With over 20 years of experience in Nutrition and R&D, she has a strong technical and scientific background that drives innovation forward. Prior to her current role, Rania assumed the position of Global Head of Product & Technology Development for Nestlé Health Science in January 2022, following her tenure as Vice President of Research and Development at the Vital Proteins business. Rania's professional journey includes her previous roles as Global Director of Science and Technology at Nestlé Health Science and Global R&D Lead for Consumer Care. Across various Nestlé research centers, she has lent her expertise to diverse sectors as well as her entrepreneurial spirit, translating scientific and technical insights into breakthrough innovations for both patients and consumers. She earned both her Bachelor's and Master's degrees in Nutrition and Dietetics from the American University of Beirut, followed by a PhD in Obesity and Nutrition from the University of Toronto. Rania aligns her mission with her passion to advance nutrition and positively impact lives through science. Her unwavering commitment to making the benefits of nutrition accessible to all remains a driving force in her personal and professional pursuits. More Episode with BIOLINKERS can be found here.

In this inspiring episode of SpreadLove in Organizations, in partnership with the Termeer Institute, host Naji Gehchan welcomes Charlene Son Rigby, CEO of Global Genes, who shares the deeply personal journey that brought her into the rare disease space. After years of searching for a diagnosis, her daughter was found to have STXBP1, a rare neurodevelopmental disorder. That life-altering moment led Charlene to co-found the STXBP1 Foundation, driven by the urgent need to accelerate research and give families like hers a path toward hope. Her story bridges science, advocacy, and parenthood—reshaping her career and purpose. Charlene discusses how this experience led her from the tech and genomics industry to nonprofit leadership, first with RareX and now with Global Genes. She highlights the organization’s mission: to empower rare disease communities through support, education, and research. Recognizing that much of early progress in rare diseases now begins with patients themselves, Charlene explains the rise of the “next-generation advocate”—families who build data, mobilize researchers, and initiate therapeutic development even in ultra-rare conditions. The merger of RareX and Global Genes was designed to strengthen this ecosystem and give advocates the tools they need to drive discovery. Looking ahead, Charlene is optimistic about the future of therapeutic development, especially as genetic tools and platform approaches open the door to faster, more scalable progress. Yet challenges remain - particularly the economic and regulatory barriers that hinder early-stage rare disease research. She calls for continued collaboration, smarter infrastructure, and systems designed to make innovation accessible to even the smallest patient communities. Above all, Charlene emphasizes leadership rooted in clarity, conviction, and hope - standing tall in what matters as we work toward cures for all. "Really focusing on what matters, and standing tall in that, is so important." MEET OUR GUESTS Charlene Son Rigby, CEO of Global Genes. Charlene Son Rigby is Chief Executive Officer of Global Genes. Charlene has spent her career building organizations at the intersection of data, technology, and life sciences. Charlene led the merger between Global Genes and RARE-X, a health technology nonprofit. She was previously Chief Business Officer at Fabric Genomics and held executive roles at enterprise software and genomics companies, including Oracle and Doubletwist. She started her career in neuroscience research at Roche. When Charlene’s daughter was diagnosed with a rare genetic disease, she co-founded the STXBP1 Foundation. She is committed to finding a cure for her daughter’s disorder. Charlene’s unplanned connection between her personal life and profession has helped push forward the search for a cure for her daughter and kids like her, and given her work deeper meaning. Charlene is a Termeer Scholar. She holds a B.A. in Human Biology from Stanford University and an M.B.A. from the Haas School of Business at U.C. Berkeley. More episodes with Termeer Institute can be found here, or on your favorite Podcast App.

In this inspiring conversation, Naji welcomes Sekhar Naik, a serial entrepreneur, aviation enthusiast, long-distance runner, and community builder who believes deeply in authentic human connection. Sekhar shares his remarkable journey from growing up in a small town in South India to navigating the bustling streets of Mumbai, exploring opportunities in Dubai, and finally coming to the United States for his MBA. His early experiences — marked by hustle, curiosity, and reinvention — shaped his path toward entrepreneurship and taught him the power of storytelling and adaptability. Sekhar reflects on how his values around ethical and empathetic growth crystallized later in life, especially after experiencing the culture of innovation and fairness in the U.S. He credits his father’s principled influence, financial insecurities in childhood, and the challenges he witnessed in India’s textile industry as key drivers behind his desire to control his own destiny. These experiences informed his belief in taking thoughtful risks and “picking where to put your hard work,” a philosophy that guided him from turning down a secure corporate job to founding his own company as an immigrant without a safety net. Today, Sekhar leads MResult, a technology consulting company that grew from a one-person operation into a global firm of over 1,000 employees — with no sales team, scaling entirely through trust, word of mouth, and excellence. He shares how the company evolved from data and analytics into cloud, digital, and AI/ML solutions, always staying agile and grounded in deep client relationships. At the heart of MResult’s success is Sekhar’s unwavering commitment to people-to-people connection—an ethos reflected in the company’s culture, his philanthropic work, and his belief that authentic relationships and purpose-driven innovation are the true engines of enduring impact. "You have to pick where you put your hard work — success isn’t just effort, it’s choosing the right place to apply it." MEET OUR GUESTS Sekhar Naik, Founder and CEO at MResult. Sekhar Naik is a serial entrepreneur, business leader, aviation enthusiast, long-distance runner, and above all a community builder who believes in the innate power of authentic people-to-people connections. He is the recipient of Karnataka Rajyotsava Award, one of highest civilian honors bestowed by the Government of Karnataka, India. As the founder of MResult, Sekhar has built a foundation of ethical and empathetic commercial growth by serving as a trusted advisor to a select group of respected global brands. His mantra of success is enabling and empowering people to take decisions and lead with confidence. His belief in the capability of people goes beyond the traditional yardstick of qualifications and expertise to intent and hunger to do more, do better. This is reflected in a culture of customer excellence. Sekhar is also a co-founder and investor in a variety of startups, providing them with both mentoring as well as financial support. In his commitment to pay it forward he is a major donor of YMCA Naik Family Branch in Mystic, Connecticut. An accomplished commercial pilot with Instrument, and Jet Type Ratings, Sekhar is available to clients wherever they might be. When not flying or mentoring the MResult team, Sekhar is passionate about running and has completed both the New York and Philadelphia marathons. He is a tech enthusiast constantly exploring new frontiers. But beyond this all, he is a storyteller, a lifelong learner, and a believer in investing in relationships that transcend transactional limits. Sekhar is committed to academic partnerships that explore leading edge innovation and investments in cutting edge technologies around Gen AI and Biotechnology companies. On the personal front, he is very grateful for his family and the privilege of leading a high performing team solving some of the industry’s most complex challenges.

In this inspiring episode of Spread Love in Organizations, Naji Gehchan welcomes Vanessa Almendro Navarro, Vice President and Head of Science and Technology Innovation at Danaher. Vanessa shares her powerful personal story — from growing up in Spain as the first in her family to attend college, to witnessing cancer’s impact on her loved ones, and ultimately dedicating her career to driving innovation in oncology and biotechnology. Her journey from academic research at Dana-Farber to leading enterprise innovation at Danaher reflects her deep commitment to transforming ideas into tangible impact for patients. Vanessa discusses how she bridges AI-enabled R&D, commercialization, and innovation to accelerate drug discovery and development. She emphasizes the importance of focusing innovation on solving real problems, being pragmatic rather than chasing the “next shiny thing,” and ensuring that technologies meaningfully advance patient outcomes. She sees the convergence of AI, biotechnology, and robotics as a pivotal moment — an “innovation revolution” — that could redefine how we discover and deliver healthcare solutions. Reflecting on her leadership journey, Vanessa highlights humility, resilience, and collaboration as essential traits for leaders in healthcare. Her guiding philosophy — “Don’t give up; we’ll figure it out” — captures her approach to overcoming challenges and inspiring others. Vanessa also shares her work with the Brain Tumor Investment Fund, where she supports translating early research into new therapies for patients. She calls on leaders to embrace this era of possibility with focus, courage, and humanity, because, as she reminds us, “Patients are not waiting.” "Don’t tell me no, tell me how. There’s always an opportunity to move forward." MEET OUR GUESTS Vanessa Almendro Navarro, Vice President, Head of Science & Technology Innovation at Danaher Corporation. Vanessa Almendro Navarro, PhD, MBA, is a life sciences executive who builds at the intersection of innovation, AI-enabled R&D, and commercialization. As Vice President and Head of Science & Technology Innovation at Danaher, she leads enterprise innovation and operating-model modernization across a global portfolio. She designed and scaled the Danaher Beacon distributed R&D program with leading academic partners, launched the Danaher Nexus intrapreneurship pipeline, established the Danaher Antibody Capability Center, and created the Danaher Summits to connect operating companies with top domain expertise. Previously, Vanessa co-founded and led the Brain Tumor Investment Fund; served as Head of Strategy & External Innovation at Eisai and Head of Strategy & Operations at Repertoire Immune Medicines; and held scientific and commercial roles at Vertex. Earlier in her career, she was a research fellow at Dana-Farber Cancer Institute/Harvard Medical School. She holds a PhD in Biochemistry & Molecular Biology (University of Barcelona) and an Executive MBA (MIT). Her expertise spans venture origination, IP strategy, translational development, partnerships and BD, and capability building in diagnostics and therapeutics. She serves on the boards of the Brain Tumor Investment Fund and MIT Sandbox and is a member of the ARM CEO Advisory Council.

In this special episode of Spread Love in Organizations, Naji sits down with Rose Saia, Executive Director of the Centre Street Food Pantry, to explore the deep connection between food, health, and dignity. Rose shares her powerful personal story — from growing up food insecure in South Boston to leading a community-driven food relief organization that now serves six Greater Boston communities. Drawing from her lived experience and leadership through the pandemic, Rose reflects on transforming Centre Street’s model to ensure equitable, dignified access to nutritious food for families in need. She discusses how food insecurity — often hidden even in affluent areas — is not only a social issue but also a public health crisis that intersects with housing, income, and healthcare access. Rose and Naji explore what leadership looks like in times of crisis, how communities can mobilize around empathy and purpose, and why solving hunger requires partnerships across health systems, local organizations, and individuals. Despite the challenges, Rose’s message is one of resilience and hope: our shared humanity drives us to help one another—and through food, we can touch lives and health in the most fundamental way. "When everything said we couldn’t, our community proved we can." MEET OUR GUESTS Rose Saia, Executive Director at Centre Street Food Pantry. Rose Saia Executive Director of Centre Street Food Pantry. Rose joined Centre Street in 2019 as a part-time Pantry Manager. When the pandemic began, she pivoted the operation to a new program and distribution model to address the exponential increase in food insecurity. She became Executive Director in 2021. Prior to joining Centre Street, she was Pantry Director for Open Table, a Metrowest regional grocery and meals agency. Her experience in nonprofit organizations includes being a member of the board of directors and marketing chair for The Capital Network and WEST (Women Entrepreneurs in Science and Technology), and as a CEO coach for women leading high-growth businesses at The Commonwealth Institute. Her professional career is anchored in high technology, where she was a leader of technical, product marketing, and business development teams for startups and global providers. She was the CEO and co-founder of a network security consulting and product company that was acquired by Juniper Networks. Rose is also a published writer and professional true-life storyteller who has appeared on local stages and on the national television series, “Stories from the Stage.” Visit and help Centre Street Food Pantry. Donate here.

In this episode of SpreadLove in Organizations, Naji is joined by Jean-Noël Pellegrin and Alain Eudaric, two veteran leaders in biotech and pharma, to discuss their new book, The Thriving Biopharma Business. With decades of experience shaping strategy, finance, and innovation across global markets, they share how purpose, clarity, and collaboration fuel success in one of the world’s most complex industries. Both guests describe their journeys — from engineering, finance, and corporate leadership at major companies like Sanofi — to helping biotech and pharma leaders align science, strategy, and market needs. Their mission through their book is clear: to help biotech innovators turn groundbreaking ideas into real-world impact. Jean-Noël and Alain dive into the lessons behind The Thriving Biopharma Business, highlighting key principles that drive sustainable growth in life sciences. They explore how companies like Moderna and Vertex Pharmaceuticals turned uncertainty into opportunity through bold strategy, storytelling, and disciplined leadership. The discussion brings to life their concept of integrative leadership — a model that connects perspectives across R&D, regulatory, finance, and commercial teams to accelerate decision-making and value creation. Through vivid examples of M&A integration and strategic partnerships, they illustrate how restraint, empathy, and emotional intelligence often determine whether innovation thrives or stalls in complex corporate settings. The conversation closes on the human side of biotech leadership — purpose, resilience, and love. The authors reflect on how storytelling and empathy are as crucial as data in convincing investors, partners, and patients to believe in a vision. They emphasize that thriving in biotech requires relentless curiosity, business acumen, and the courage to lead with compassion. As Jean-Noël and Alain put it, spreading love in organizations means creating environments where collaboration, integrity, and shared purpose drive breakthroughs that truly change lives. "Great outcomes demand more than science — they require decisive leadership.” – Alain Eudaric “Integrative leadership turns transactions into true partnerships built on trust.” – Jean-Noël Pellegrin MEET OUR GUESTS Alain Eudaric, President Idea Pathways. MEET OUR GUESTS Jean-Noël Pellegrin, Sr Director Valuation and Finance Support to Business Development, M&A at Sanofi. Alain Eudaric brings over 30 years of global expertise in biopharma, life sciences, and consulting, specializing in strategy, M&A, alliances, and innovation-led growth. He has held leadership roles at Kearney, Thermo Fisher Scientific, and Parexel International, driving transformative programs and business success. As President of Idea Pathways, Alain focuses on driving operational excellence and fostering innovative growth strategies for the biopharma industry. He is an alum from Harvard Medical School, Johns Hopkins University, MIT, Purdue University, and Ecole Centrale de Lille with advanced degrees in Biotech, Business, Science, and Engineering. Jean-Noël Pellegrin has over 15 years of expertise in M&A and business development, with a proven track record of contributing to several hundred transactions. He began his career at EY before most recently joining Sanofi, where he has spent the last 20 years in France and the United States. His 30 years of combined experience across global public company finance, audit, accounting, and strategic transactions make him a trusted expert in valuing life sciences assets and structuring complex deals. He is an alum of Babson College and Sciences Po, with advanced degrees in Business and Finance. Find their book here!

In this special episode of SpreadLove in Organizations, in partnership with the Boston Biotechnology Summit, Naji Gehchan welcomes Benjamin Hadida, co-founder and CEO of Exeliom Biosciences, a French clinical-stage biotech company pioneering microbiome-based immunomodulation therapies. Benjamin shares his inspiring journey from studying finance and molecular biology to creating his “dream job” — building a biotech company developing novel drugs from scratch. Motivated by the strong scientific potential in France and the desire to bridge academia with industry, he co-founded Exeliom to transform promising academic discoveries into real-world treatments. Under his leadership, Exeliom has raised $29 million to advance EXL01, a first-in-class therapy targeting the innate immune system, now in Phase 2 trials for oncology, inflammatory bowel disease, and infectious diseases. Benjamin reflects on the early challenges of founding a biotech without a predefined roadmap, emphasizing the value of curiosity, humility, and adaptability. With no regulatory precedent or traditional C-suite structure, his team built a unique organization focused entirely on what their lead program needed to reach the clinic — not on personal titles or egos. This disciplined focus, coupled with clear alignment among co-founders and scientific advisors, allowed Exeliom to move an academic concept into advanced clinical trials. He highlights one key leadership lesson for biotech founders: always ask, “What does the program need?” — a mindset that drives both strategic clarity and organizational culture, ensuring every decision serves the science and the patients it aims to help. Benjamin also dives into the science behind Exeliom’s groundbreaking approach. Rather than targeting a molecule, their innovation emerged from clinical observations linking patient responses to immunotherapy with gut microbiome composition. Exeliom’s therapy leverages a specific bacterial strain, Faecalibacterium prausnitzii, to modulate macrophages via the innate immune receptor NOD2 — effectively enhancing immune responses depending on disease context. Looking ahead, Benjamin sees EXL01 as an add-on immunomodulator that could boost responses to checkpoint inhibitors or anti-TNF treatments. His biggest challenge now is educating pharma partners about the real potential of microbiome-based therapies, often misunderstood after past industry missteps. "Put yourself behind others, not in front of them… You cannot be successful without love." MEET OUR GUESTS Benjamin Hadida, Co-Founder & CEO of Exeliom Biosciences. Benjamin Hadida is co-founder of Exeliom Biosciences, a clinical-stage biotech company founded in 2016 in France, winner of the Biotech Summit Pitch this year. With experience spanning investment banking, venture capital, regulatory affairs, biotech operations, and applied research, Benjamin brings a multidisciplinary perspective to biotech innovation. He holds master’s degrees in Management from ESSEC Business School, and Molecular and Cellular Biology from Sorbonne. Under his leadership, Exeliom has raised $29 million to develop EXL01, a groundbreaking microbiome-based immunomodulator targeting the innate immune system. This first-in-class therapy is now in Phase 2 trials for Immuno-oncology, Inflammatory Bowel Diseases and Infectious Diseases.

In this inspiring episode of SpreadLove in Organizations, in partnership with the Termeer Institute, host Naji Gehchan welcomes Dr. Fernando Vieira, CEO and Chief Scientific Officer of the ALS Therapy Development Institute (ALS TDI). A physician-scientist and engineer, Fernando shares his deeply personal journey from aspiring inventor to leading one of the world’s foremost non-profit biotechs dedicated to ALS. His passion stems from the loss of his close friend to the disease, which shaped his life’s mission - to translate scientific discovery into real treatments for people living with ALS. Fernando offers an inside look into the unique non-profit biotech model at ALS TDI -an organization that combines scientific rigor with mission-driven purpose. With integrated research programs spanning cell biology, pharmacology, and clinical data, ALS TDI develops and validates therapeutic targets, often spinning off intellectual property to for-profit partners to advance drug development. Fernando highlights the advantages of staying focused on a single disease area, building institutional knowledge, maintaining long-term commitment, and ensuring every effort serves the ALS community. He also explores the promise and challenge of rare disease research, emphasizing the complexity and need for multiple targeted therapies to address ALS’s many subtypes. Looking ahead, Fernando expresses optimism about emerging technologies, AI applications, and omics data transforming ALS research. From digital biomarkers and machine learning to novel therapeutic modalities, he believes the field is entering a new era of precision and hope. Reflecting on leadership, he defines it as servant leadership: serving the mission and his team with empathy and humility. As a recent Termeer Fellow, he praises the Foundation for fostering mentorship and connection among healthcare innovators. "Think about the people that you're trying to serve, and meet them where they are. Understand their needs, and let that guide everything you do." MEET OUR GUESTS Fernando Vieira, CEO and CSO at ALS Therapy Development Institute, Termeer Institute Fellow. Fernando Vieira has over 20 years of dedication to advancing ALS research and treatment development at the ALS Therapy Development Institute (ALS TDI), a non-profit biotech company. Dr. Vieira has progressed through various leadership roles at ALS TDI, culminating in his current positions as Chief Executive Officer and Chief Scientific Officer. He leads a team of over 25 researchers, overseeing target discovery, drug discovery, biomarker development, and translational ALS research. Having lost his closest friend to ALS, Fernando is deeply committed to translating scientific discoveries into clinical applications that benefit people with ALS. Fernando’s work integrates preclinical pharmacology, multi-omics, and digital outcome measures, driving the preclinical validation of multiple drugs, including tegoprubart, now in clinical development for ALS, along with kidney transplant. He has worked to establish ALS TDI as a hub for innovative ALS research infrastructure, fostering collaborations to enhance disease monitoring and therapeutic outcomes. Fernando is a recognized leader in ALS research, affirmed by his roles on the Research Committee of ALS ONE and the International Alliance of ALS/MND Associations Research Directors Forum. He holds multiple patents for novel therapeutic approaches for ALS and has contributed to publications in multiple high impact journals such as Nature Communications, Nature Genetics, and Science Translational Medicine. Fernando earned a degree in biological engineering from the University of Florida and his MD from Harvard Medical School. Outside of his professional life, Dr. Vieira is a dedicated father to a high school-aged son in Newton. He actively participates in his son's activities with a local Scouting America troop. In his free time, he enjoys running, hiking, and playing basketball.

In this special episode of SpreadLove in Organizations, produced in partnership with the MIT Club of Boston BioSummit, Naji Gehchan welcomes Dimitrios Skaltsas, CEO and co-founder of Intelligencia AI. Founded in 2017, Intelligencia is a pioneer in applying artificial intelligence, data science, and biomedical expertise to transform decision-making in pharmaceutical R&D. Dimitrios shares his remarkable journey from studying law in Greece to leading one of the most innovative companies in healthcare AI. Inspired by his roots and driven by a deep sense of purpose, he reflects on the pivotal moments that shaped his career — from consulting at McKinsey to discovering a passion for innovation in life sciences — and how love, family, and giving back have guided his mission. Dimitrios dives into the origins of Intelligencia AI and the crucial problem it set out to solve: improving R&D productivity and redefining how risk is assessed in drug development. By building machine learning models to predict the probability of clinical success, Intelligencia provides pharmaceutical companies with a robust decision-support tool, helping them prioritize programs, optimize portfolios, and ultimately bring new therapies to patients more effectively. Dimitrios emphasizes that AI should complement, not replace, human judgment, serving as a powerful tool to support intuition with data-driven insights. As the company continues to grow, it is expanding into new therapeutic areas, geographies, and functionalities, with a focus on making drug development smarter, faster, and more predictive. The conversation also explores the human side of leadership and innovation. Dimitrios shares how his love of painting — from abstract canvases to portraits of people he knows - mirrors his leadership philosophy: balancing big-picture creativity with deep human connection. He defines leadership as a responsibility to serve others and sees clinical trials as both a blessing and a challenge; essential for patient safety but ripe for innovation. On AI, he is optimistic yet cautious, recognizing its transformative potential alongside its risks if not guided by ethics and discipline. This episode offers a rich exploration of purpose-driven leadership, the intersection of art and science, and the future of AI in reshaping how life-changing medicines are discovered and developed. "AI is a huge opportunity for life sciences, but without ethics, it can mislead us." MEET OUR GUESTS Ditrios Skaltsas Co-Founder & CEO, Intelligencia AI. As the CEO and co-founder of Intelligencia AI™, Dimitrios Skaltsas drives the AI-driven technology organization's business and investment growth strategy while overseeing critical functional areas of the multidisciplinary global team. Founded in 2017, Intelligencia AI leads the way in leveraging proprietary data, biomedical expertise and artificial intelligence (AI) with its patented technology to address significant challenges in the pharmaceutical industry. These challenges include lengthy drug development timelines, excessive costs, and unsustainable return on investment (ROI). Its suite of AI-powered solutions delivers actionable insights crucial in mitigating risks and enhancing decision-making associated with drug development by providing an accurate, unbiased assessment of a drug’s probability of success.  In 2024, the company received a U.S. patent for its accurate and transparent probability of drug success assessments. It also earned its inaugural spots on the Inc. Regional (Northeast) and Inc. 5000 for the first time. The Healthcare Technology Report recognized it as one of the Top 100 Healthcare Technology Companies. In 2021, the company completed its Series A funding and was named one of Forbes's Top AI Companies to Watch. During this time, Dimitrios played a pivotal role in establishing a strategic partnership with ZS, a global professional services company. Before tapping into his entrepreneurial spirit and co-founding Intelligencia AI, Dimitrios spent over a decade in various leadership roles within the healthcare and life sciences sectors. He holds an MBA from INSEAD and a law degree from University College London (UCL) and the University of Athens. In his leisure time, you can find him painting or enjoying the Greek countryside.

In this episode of SpreadLove in Organizations, I am joined once again by my longtime friend and colleague, John Bamforth, to celebrate the launch of his new book Race to Innovation. John’s remarkable journey has taken him from his roots in Wigan, England, to building global brands at Eli Lilly, and most recently, leading the Eshelman Institute for Innovation at UNC-Chapel Hill. He was my very first guest when I started this podcast four years ago, and it’s a joy to welcome him back as we reflect on his career, his growth, and the bold ideas he is now championing. John shares the story behind Race to Innovation, which highlights the often-overlooked history of innovation and entrepreneurship in marginalized communities, particularly African American communities. The book blends untold stories of past trailblazers with interviews of today’s innovators, all grounded in the belief that unlocking potential in underrepresented groups creates value for all of us. This is not a zero-sum game; rather, encouraging diversity of thought and entrepreneurship helps societies thrive together. Our conversation goes beyond the book, touching on the meaning of innovation, the intentionality required to build diverse, trusting teams, and the essential role of purpose in uniting people around bold goals. John’s insights remind us of the power of assuming potential in every individual and of leading with genuine care for one another. His vision is a hopeful call to see difference not as division but as a force for solving the world’s most pressing challenges - together. "Innovation starts with assuming potential in every individual - and unlocking it benefits us all." MEET OUR GUESTS John P Bamforth, independent Director for Humacyte and a member of the commercialization committee. Dr John Bamforth PhD is an independent director for Humacyte Inc (NASDAQ: HUMA) and a member of the commercialization committee. In addition, he has served on the Boards of the Structural Genomics Consortium (https://www.thesgc.org) and READDI (https://readdi.org). On the READDI Board, John recruited 4 independent Board members including Sen Richard Burr and Lydia Ogden PhD (JNJ) and he chairs the compensation committee. He is an advisor to several privately owned biotech and healthcare companies and is an active investor. John is co-founder of the B and M Impact Foundation (BMimpact.org) which is focused on creating wealth and health in disadvantaged communities. John had a 30-year career at Eli Lilly and Company culminating in the Chief Marketing Officer (CMO) role from 2016 to his retirement in 2018. He was also CMO of Lilly's $10B US operation from 2012-2016. Over his career at Lilly John was known for building highly engaged teams and launching multiple brands across the globe. Probably, his best-known success was the building of Cialis globally, the $2B a year blockbuster brand. On his retirement from Lilly, John was hired to lead Eshelman Innovation at the University of North Carolina, Chapel Hill, an institute that was founded by a $100M gift, the largest gift in UNC's history. The institute leverages industry practices and the University's $1.5B research enterprise to develop novel therapeutics alongside digital health technologies. He stepped down from the role in 2025 after 6 years to focus on his board work and philanthropic endeavors. John has a pharmacy degree and PhD from his education in the United Kingdom. Pharmavoice named John one of Pharma's top 100 'Inspirational Leaders' in 2007 and his alma mater, Aston University, awarded him an Honorary Doctorate for service to the Pharma Industry in 2012. John lives in Chapel Hill, North Carolina with his wife Sue, and has two adult children, Thomas and Rebecca. More about the Book on this link!

In this special episode of SpreadLove in Organizations, I had the honor of hosting Dr. François Nader and Khalil Barrage, the visionary co-founders of BioLink. This New York–based nonprofit is on a mission to connect biosciences professionals of Lebanese origin around the world, while building a sustainable life sciences ecosystem in Lebanon. François shared his inspiring journey from physician in Lebanon to global biotech leader, including turning around NPS Pharma before its $5B acquisition by Shire. Khalil reflected on his path from Lebanon to becoming one of the most active biotech investors through The Invus Group, with landmark investments in companies such as Moderna. Both leaders opened up about the origins of BioLink, which were born out of tragedy but fueled by hope. In the aftermath of the Beirut port explosion, they witnessed the strength and generosity of the Lebanese diaspora in the life sciences community. This moment of crisis revealed an incredible network of Lebanese talent across the industry and sparked the idea to create a global platform. BioLink was established not only to bring these leaders together, but also to lay the foundation for a life sciences economy in Lebanon that can create opportunities for the next generation. Throughout our conversation, François and Khalil emphasized values of vision, resilience, and credibility in leadership. They reminded us that true leadership shines in times of crisis, and that success in biotech requires grit, integrity, and long-term commitment. Above all, they shared a dream: to harness the collective power of Lebanese professionals worldwide to contribute back to Lebanon and build something enduring. This episode is a testament to purpose-driven leadership, collaboration, and the belief that together, we can inspire change. "Leaders show the most leadership during a crisis." -François Nader "In biotech, there are no shortcuts — integrity and the right team matter.” - Khalil Barrage MEET OUR GUESTS Francois Nader chairman of GEn1E Lifesciences, and board director of Moderna and Ring Therapeutics. MEET OUR GUESTS Khalil Barrage Managing Director at The Invus Group. This is a special episode, the first of a series in partnership with Biosciences Lebanese International Network – BioLink. This New York-based non-profit is on a mission to build a global community of professionals in biosciences of Lebanese origin, like me, and it turns out, there’s quite a few of us. Most interestingly, it has set a bold vision, which is to catalyze a life sciences ecosystem in Lebanon by working with local talent and academic centers, with the support of the Lebanese diaspora community. This is an ambitious goal, but BioLink.org’s founders Dr. Francois Nader and Khalil Barrage are some of the most accomplished people in the industry, and if anyone can pull it off, they can. I’m thrilled to have them with me today! Francois is a pharma veteran who sits on the board of several biopharma companies. He is chairman of GEn1E Lifesciences, and a board director of Moderna and Ring Therapeutics, as well as a senior advisor to Blackstone Life Sciences. Francois became well known within the industry, when he took the helm of NPS Pharma in 2006. The company was then on the verge of insolvency. Francois turned it around and sold it less than a decade later for more than $5 billion to Shire.  Khalil is a managing director at The Invus Group, a New York-based global investment firm. He established the Public Equity Group which invests in emerging innovative biotech companies, and co-manages private biotech investments, making Invus one of the most active investors in biotech, according to PitchBook. Khalil also sits on the board of several biotech companies, including ElevateBio, Sensorion, Onxeo, Protagenic Therapeutics, and Orthobond.

In this episode of Spread Love in Organizations, Naji Gehchan had the pleasure of hosting Catharine Smith, the inaugural Executive Director of the Termeer Institute. The Institute honors the legacy of former Genzyme CEO Henri Termeer by supporting biotech leaders who are driven by patient impact. Catherine shared her powerful journey, from growing up with limited access to healthcare, to leading initiatives at the Clinton Foundation and Harvard, and now shaping a movement that empowers early-stage biotech CEOs to tackle some of healthcare’s biggest challenges. Her personal story, rooted in seeing healthcare as a human right, set the stage for our inspiring conversation. Throughout our discussion, Catherine highlighted the importance of leadership as a catalyst for systemic change. Drawing from her experience in hospital medicine, primary care, and crisis response, she emphasized that effective leadership goes beyond technical expertise —it’s about training, mentoring, and empowering people to drive meaningful improvements in patient care. At the Tamir Foundation, this philosophy translates into supporting biotech founders not only with resources and technical skills, but also with values-aligned networks, mentorship, and leadership development tailored to their journeys. Catherine also shared her perspective on the future of biotech as a powerful lever for change in healthcare. From the promise of rare disease therapies to the growing energy in women’s health, she stressed how science and innovation must be matched with responsibility, equity, and human-centered leadership. For her, the “human variable” is the most crucial factor in whether breakthroughs succeed in transforming lives. As we closed, Catherine reminded healthcare leaders to hold onto their “why,” seek partnerships, and focus on solving big problems together. It was a conversation full of hope, responsibility, and a call to action for leaders across healthcare and biotech. "Biotech can be a lever to change healthcare." MEET OUR GUEST Catharine Smith, Executive Director of the Termeer Institute. Catharine Smith serves as inaugural Executive Director of the Termeer Institute (Former Termeer Foundation), which carries on the bold legacy of former Genzyme CEO Henri Termeer, who was committed to mentoring emerging leaders and whose dedication to patients resulted in groundbreaking treatments for rare diseases. The Termeer Foundation understands that bringing new treatments to patients is grueling work with a low probability of success and believes we can improve these odds by positively impacting the human variables in healthcare. By supporting biotech leaders, the Foundation seeks to increase the probability of creating cures and solving healthcare’s greatest challenges. Prior to the Termeer Foundation, Catharine served as the CEO of the Clinton Health Matters Initiative at the Clinton Foundation where she led a team focused on stigma reduction and overdose prevention related to the opioid epidemic. Before that role, Catharine was the Executive Director of the Harvard Center for Primary Care where she led business development, strategy, and operations for a think-tank focused on improving value-based, patient-centered care. Catharine holds a master’s degree in business administration from the Massachusetts Institute of Technology and a graduate degree in social science research from the University of Chicago.

In this episode, Naji Gehchan welcomes Selin Kurnaz, CEO and co-founder of Massive Bio, a health tech company using AI and data-driven solutions to expand access to cancer clinical trials. Selin shares her personal journey from a structured career in engineering and private equity to founding Massive Bio after her family’s experience with cancer. What started as a side project quickly became her full-time mission, as she realized the immense challenges and dedication required to drive change in healthcare. Since 2015, she has led Massive Bio to impact over 160,000 patients worldwide, with a focus on underserved communities and equitable access to clinical trials. Selin highlights the importance of applying engineering principles to clinical operations, particularly in solving the long-standing challenge of patient recruitment in oncology trials. By combining systematic problem-solving with regulatory knowledge, Massive Bio addresses inefficiencies across the patient enrollment journey—identification, pre-screening, and last-mile enrollment. She explains how AI enables scalability, reducing the time it takes to match patients with clinical trials from months to minutes. This approach not only empowers patients to advocate for themselves but also helps physicians and pharma companies accelerate drug development, creating both individual and population-level impact. Discussing leadership and growth, Selin emphasizes resilience, teamwork, and the importance of early adopters in driving healthcare innovation. She speaks candidly about the challenges women face in senior roles within health tech and the need for true meritocracy. At Massive Bio, she fosters a flat, mission-driven culture where every team member feels empowered and connected to the purpose of improving patients’ lives. Her closing advice to healthcare leaders is to remain resilient, embrace humility, and stay grounded—focusing on what truly matters: health, team, and impact. "I’m not seeking fairness in life, but success in the unfairness of life." MEET OUR GUEST Selin Kurnaz, CEO and co-founder of Massive Bio, a health tech company improving access to cancer clinical trials through AI and data-driven solutions. Selin Kurnaz is the CEO and co-founder of Massive Bio, a health tech company improving access to cancer clinical trials through AI and data-driven solutions. She holds a PhD in Mechanical Engineering and brings over a decade of experience in life sciences strategy and operations. Inspired by her family’s cancer journey, Selin launched Massive Bio in 2015 to make cutting-edge treatments more accessible, particularly in underserved communities. Under her leadership, the company has onboarded over 160,000 patients and built a global network of sites, partners, and advocates. Selin is also a recognized voice for women in tech and digital health innovation. About Massive Bio: Massive Bio is a healthcare technology company using AI to match cancer and rare disease patients with clinical trials and optimize drug use for better outcomes. Founded to address the barriers patients face in accessing advanced treatments, the platform simplifies and personalizes the clinical trial journey. With over 160,000 patients onboarded and partnerships with top pharma companies across 17 countries, Massive Bio is transforming oncology care. Its solutions reduce inefficiencies, accelerate drug development, and improve treatment access globally. The company is now expanding beyond trial matching into broader oncology services to become a leading data-driven cancer care platform.

In this episode of Spread Love in Organizations, Naji Gehchan welcomes Christy Fernandez-Cull, CEO of DaVinci Wearables and a trailblazer in tech and health innovation. Christy shares her inspiring journey from childhood curiosity — designing a cereal dispenser to let her hardworking parents sleep in — to leading groundbreaking work at companies like Apple, Waymo, and Google. With a PhD from Duke and an MBA from MIT, Christy blends deep technical expertise with visionary leadership, always guided by a moral compass instilled by her family and a relentless curiosity about the world. Christy introduces her current venture, DaVinci Wearables, with the bold ambition of becoming the “body API for better health.” She describes a future where garments not only clothe us but also provide real-time biometric insights, especially focused on women’s health, a historically underserved field. With partnerships across universities and health systems, DaVinci is building a wearable ecosystem that tracks hydration, hormones, nutrition, and physical activity, empowering users through a smart companion app that educates and nudges healthier habits. Their unique platform blends data, personalized coaching, and community, aiming to democratize body intelligence for every stage of a woman’s life. Throughout the conversation, Christy speaks candidly about the challenges and joys of entrepreneurship, especially as a female founder in health tech. She emphasizes the importance of empathy — both toward others and oneself — and encourages founders to stay anchored in purpose by connecting directly with the people they serve. Christy’s reflections on leadership, equity in women’s health, and the role of love and service in organizations offer powerful inspiration for healthcare leaders seeking to drive meaningful change. "If you need to feel inspired, go directly to your customer… They’ll remind you why you started." MEET OUR GUEST Christy Fernandez-Cull, CEO of DaVinci Wearables and former leader of sensing teams at Waymo (Google Self-Driving) and Lyft's Self-Driving Division. Dr. Christy Fernandez-Cull is CEO of DaVinci Wearables and former leader of sensing teams at Waymo (Google Self-Driving) and Lyft's Self-Driving Division. She played a key role at Apple, contributing to autonomous systems and releasing the first LiDAR module in the 2020 iPad. Dr. Fernandez-Cull has experience in Defense technologies at MIT Lincoln Laboratory and consumer products at Apple. She advises VCs and startups in mobility, autonomous vehicles, and digital health, and serves on several boards. She holds a Ph.D. from Duke University and an MBA from MIT and lectures at Columbia University and MIT. Longer Dr. Christy Fernandez-Cull is the CEO of DaVinci Wearables. Previously, she led the sensing and perception system’s teams at Waymo - formerly Google Self-Driving. She was also the Head of Sensors at Lyft Level 5 Self-Driving Division, leading sensor architecture for Lyft vehicle platforms — designing machine eyes to help transform transportation of the future. Prior to Lyft, she was a senior technologist at Apple spanning autonomous systems and the Camera and Depth Hardware team that released the first-of-kind Light Detection and Ranging module in the 2020 iPad. She has spanned both the development of Defense technologies at MIT Lincoln Laboratory and at-scale consumer-product technologies at Apple. She is a senior science advisor to multiple VCs and startups in the areas of sensors and systems for mobility applications, autonomous vehicles and digital health and wearables. She’s a Board member of Omnitron and a Venture Partner and Deep Tech Advisor at L’attitude Ventures and serves on a non-profit board. She received her MS and Ph.D. in Engineering from Duke University and MBA from MIT and enjoys mentoring in STEM/STEAM fields and serves as a adjunct/lecturer at Columbia University, guest lecture and AI practitioner at MIT-LL and MIT Media Lab.

In this episode of Spread Love in Organizations, I had the pleasure of hosting Michael Pietrack, a seasoned recruiter in the pharmaceutical industry with nearly two decades of experience. Michael shared his fascinating journey, starting as a college baseball coach and transitioning into pharmaceutical recruiting by chance. Over the years, he has placed more than a thousand professionals, making a significant impact on the industry by connecting top talent with critical roles in medical affairs and beyond. Michael’s commitment to improving healthcare by enabling the success of industry leaders was evident as he discussed how recruiting for this field has become a purposeful mission for him. Michael offered invaluable advice for both hiring managers and job seekers. For hiring managers, he emphasized the importance of clarity in defining roles, avoiding the pitfall of hiring clones, and trusting one’s gut instinct when making decisions. For candidates, he highlighted the need to have a clear career strategy, prioritize the “people” factor when considering opportunities, and be willing to take risks for growth. Michael also shared insights from his podcast, The PharmaVerse, where he explores leadership across the pharmaceutical universe. One key takeaway from his interviews is the central role of genuine care in effective leadership—a value deeply aligned with our podcast’s focus on spreading love in organizations. "Leadership is leading from the front while ensuring no one is left behind." MEET OUR GUEST Michael Pietrack Practice Lead for Pharma and Biotech recruiting team at Kaye/ Bassman International Corp. Michael Pietrack has been recruiting in the Pharmaceutical Industry for nearly 20 years. He and his team have successfully placed more 1,000 Pharmaceutical professionals during that time, leaving a positive impact on the industry. Michael started his recruiting career with The Alpine Group, where he led the Medical Affairs Search Practice. In 2015, Michael co-founded TMAC Direct, an executive search firm exclusively devoted to Medical Affairs. Under Michael’s leadership, TMAC Direct was named one of the Top US Executive Search Firms by Forbes. In 2023, Michael joined Kaye/Bassman to lead the expansion of the already established and high-performing Pharmaceutical and Biotechnology Search Practice. Aside from recruiting, Michael is also a speaker, recruiting trainer, and an accomplished author and was recognized as one of Pharma’s 100 Most Inspiring People by PharmaVoice. Michael is also a fellow podcast host on The Pharamaverse Podcast, where he engages in insightful conversations with industry leaders. 

On this episode, I had the privilege of hosting Afarin Bellisario, a mentor at MIT Sandbox, author, and tech entrepreneur with an extraordinary life story. Afarin began by sharing her journey from her childhood in Iran to becoming a prominent figure in high-tech and entrepreneurship in the U.S. Growing up in a family that straddled traditional and modern Iran, she had a unique perspective on navigating the contrasting worlds of South and North Tehran. Her education, initially rooted in mathematics, became her ticket to freedom and opportunity, culminating in her studies at NYU and MIT. The tumultuous events of the Revolution profoundly shaped her, compelling her to forge a new path in America. She eloquently described how curiosity, resilience, and adaptability fueled her career, whether in corporate America or mentoring young entrepreneurs. We also delved into her debut novel, Silence Whispers, which tells the story of a young woman navigating transformative changes in her life and country. Afarin explained how this fictional character, Gohar, was inspired by both her own experiences and the rich stories of her heritage, blending historical and personal elements. Through extensive research and creative writing, she captured the complex dualities of Iranian society and the broader universal struggles of identity, resilience, and transformation. Afarin emphasized that while Gohar shares some traits with her, the character stands apart as a vehicle for exploring the broader human experience. The novel serves as both a personal exploration and a reflection on the cultural and societal shifts of her homeland. Finally, Afarin shared her philosophy on the intersection of history and technology, emphasizing how understanding the past can inform and guide our technological future. Drawing on examples from her work with startups and historical case studies, she highlighted the recurring patterns in how society reacts to radical new technologies. From the advent of radio to the rise of artificial intelligence, Afarin underscored the importance of maintaining human agency and using technology as a tool for good. Her reflections offered profound insights into leadership, innovation, and the enduring need to balance progress with humanity. "Change is inevitable; embracing it with curiosity turns challenges into opportunities." MEET OUR GUEST Afarin Bellisario Consultant, Advisor at MIT, and Author. Afarin Bellisario bridges East and West, technology and the human condition, and past and present. Born and raised in Tehran in a family with its feet in the past and its head in the future, she led a successful career in high-tech and international business in the US after earning her PhD (from Massachusetts Institute of Technology (MIT). But writing had always been her passion. Having written professionally in pre-revolutionary Iran, she has published op-eds in major papers, including the Boston Globe and an essay, Movies with my Aunt, as part of the anthology Love & Pomegranates.  Today, she mentors startups, teaches, and writes about the clash between tradition and modernity and how the past can shed light on our technology-fueled future. A music lover, she is a Cambridge Chamber Ensemble board member and writes for their newsletter as well as on Medium. Afarin continues to discover new destinations globally.

In this episode of SpreadLove in Organizations, Naji hosted Jason Bhardwaj, a seasoned life science executive and CEO of Nova Anchora. Jason shared his journey from growing up in a science-oriented household to leading biotech startups. He described how his passion for healthcare and business developed through his studies in biomedical engineering at Duke and a decade-long career in consulting. His transition from consulting to entrepreneurship reflects his drive to build impactful solutions in heatlthcare. Jason highlighted key lessons from his experience building and leading biotech teams. He emphasized the importance of finding personal gratification in the startup ecosystem, where milestones - like moving a project from concept to clinic - feel profoundly rewarding. He discussed the critical role of people decisions in virtual biotech models, stressing the importance of rigorous hiring processes and selecting the right partners to ensure a cohesive and capable core team. Jason's philosophy centers on creating an environment where each team member's unique skills contribute to breakthrough innovations. Beyond biotech, Jason shared his commitment to community and education. With two young children, he recently announced his candidacy for the Newton, Massachusetts public school committee. Inspired by a family legacy in teaching, he aims to contribute to educational development and support local families. This passion underscores his belief that learning is a lifelong journey, whether in science, business, or public service. "Find the way you want to make a difference" MEET OUR GUEST Jason Bhardwaj CEO of Nova Anchora. Jason Bhardwaj is an experienced life sciences executive with a broad background leading in startups and ~20 years working in healthcare. Currently, Jason is the CEO of Nova Anchora, developing a recombinant protein-based treatment for DEB (dystrophic epidermolysis bullosa). Prior to this, Jason served for 6 years as CEO of another dermatology-focused biotech (Follica, a drug-device combination product for alopecia). Jason has led or advised across a wide range of technologies (drugs, devices, combinations), as well as indications (e.g., Dermatology, Psychiatry, Cardiology, Ophthalmology). Prior to life science startups, Jason studied biomedical engineering (Duke), received a masters degree in business (Harvard), and developed a decade of foundational experience in consulting (Bain) working with some of the largest healthcare innovators on a full functional suite of critical challenges (e.g., growth strategy, pricing, M&A diligence, organizational and operating model alignment). Jason and his family live in Newton, MA, where he is involved in the community as a soccer coach, marathon runner, and most recently via a bid for the school committee. Find more and support Jason's mission: www.jason4newton.com